A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06153251)
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
- Stanford University Medical Center — Stanford, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Moffitt Cancer Center — Tampa, Florida
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Local Institution - 0008 — Nashville, Tennessee
- Tennessee Oncology — Nashville, Tennessee
- Swedish Medical Center — Seattle, Washington
- Hôpital Saint-Louis — Paris,
- Universitaetsklinikum Koeln — Cologne,
- Universitaetsklinikum Heidelberg — Heidelberg,
- Universitaetsklinikum Wuerzburg — Würzburg,
- Clinica Universidad de Navarra — Pamplona, Navarre
- Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca — Salamanca,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed and/or Refractory Multiple Myeloma
- Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex — Edmonton, Alberta
Explore by condition: All Relapsed and/or Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.